Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers
BackgroundIn refractory nephrotic syndrome (RNS) poorly responsive to standard therapy, combining rituximab (RTX) with Angiotensin-converting enzyme inhibitors (ACEI) and statins shows synergistic potential, yet its efficacy and podocyte effects require confirmation.ObjectiveTo assess RTX plus ACEI...
Shranjeno v:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2026-07-01
|
| Serija: | Frontiers in Pharmacology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1851207/full |
| Oznake: |
Brez oznak, prvi označite!
|